P230001/S014: ColoSense
FDA’s recorded scope: ColoSense Sample preservative shelf-life extension from the original PMA approval of 12 months to 18 months in this current supplement S014.
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 2 FDA records to the applicant name Geneoscopy, Inc.. It includes 1 original PMA approval. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from May 3, 2024 to Sep 8, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code SBB appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P230001, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 2220 Welsch Industrial Ct., St. Louis, MO, 63146. Recorded on P230001/S014, decision dated Sep 8, 2026.
System, Colorectal Neoplasia, Rna Markers And Hemoglobin Detection.
FDA’s recorded scope: ColoSense Sample preservative shelf-life extension from the original PMA approval of 12 months to 18 months in this current supplement S014.
The FDA decision dated 2024-05-03 for P230001 marks original premarket approval of ColoSense, an in vitro diagnostic test detecting colorectal neoplasia associated RNA markers and occult hemoglobin in human stool. The indication covers adults 45 years or older at average risk for colorectal cancer. The supplied record lists no supplement type, so no modification to an earlier clearance is established; the identifier alone does not connect this to a prior PMA.
Per the source statement, a positive result may indicate colorectal cancer, advanced adenomas, or serrated precancerous lesions and should be followed by colonoscopy. The statement also says ColoSense is not a replacement for diagnostic or surveillance colonoscopy in high-risk individuals. These are the applicant's stated intended uses; the record does not supply independent evidence of safety or clinical effectiveness, and it does not describe trial data, performance figures, or the composition of the RNA marker panel.
ColoSense is a qualitative in vitro diagnostic test intended for the detection of colorectal neoplasia associated RNA markers and for the presence of occult hemoglobin in human stool. A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA) or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at average-risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ColoSenseP230001/S014 | Geneoscopy, Inc. | PMA supplement | Sep 8, 2026 | FDA |
ColoSenseP230001 | Geneoscopy, Inc. | PMA approval | May 3, 2024 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 19, 2026.